[Pharmacotherapy of central oculomotor disorders].

Abstract

Nystagmus causes blurred vision due to oscillopsia, as well as impaired balance. Depending on etiology, additional cerebellar and brain stem signs may occur. We present the current pharmacotherapy of the most common forms of central nystagmus: downbeat nystagmus (DBN), upbeat nystagmus (UBN), acquired pendular nystagmus (APN), and congenital nystagmus (CGN). Recommended medical therapies are aminopyridines (4-AP) for DBN and UBN, gabapentin and memantine for CGN and APN, and baclofen for periodic alternating nystagmus (PAN).

• Authors: R Kalla, R Spiegel, J Wagner, N Rettinger, K Jahn, M Strupp
• Journal: Der Nervenarzt (Nervenarzt) Vol. 79 Issue 12 Pg. 1377-8, 1380-2, 1384-5 (Dec 2008) ISSN: 0028-2804 [Print] Germany
• Vernacular Title: Pharmakotherapie zentraler Nystagmusformen.
• PMID: 18633586 (Publication Type: Journal Article, Review)

Chemical References

• Amines
• Cyclohexanecarboxylic Acids
• gamma-Aminobutyric Acid
• Gabapentin
• 4-Aminopyridine
• Baclofen
• Amifampridine
• Memantine

Topics

• 4-Aminopyridine (analogs & derivatives, therapeutic use)
• Amifampridine
• Amines (therapeutic use)
• Baclofen (therapeutic use)
• Cyclohexanecarboxylic Acids (therapeutic use)
• Diagnosis, Differential
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Gabapentin
• Humans
• Magnetic Resonance Imaging
• Memantine (therapeutic use)
• Nystagmus, Pathologic (diagnosis, drug therapy, etiology, physiopathology)
• Vestibular Nuclei (drug effects, physiopathology)
• gamma-Aminobutyric Acid (therapeutic use)